Drug Type Small molecule drug |
Synonyms (-)-sulforaphane, (R)-sulforaphane, 4-methylsulfinylbutyl isothiocyanate + [9] |
Target |
Action inhibitors |
Mechanism HDAC inhibitors(Histone deacetylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization ![]() |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC6H11NOS2 |
InChIKeySUVMJBTUFCVSAD-UHFFFAOYSA-N |
CAS Registry4478-93-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
COVID-19 | Phase 3 | United Kingdom | 23 Nov 2020 | |
Respiratory Distress Syndrome, Adult | Phase 3 | United Kingdom | 23 Nov 2020 | |
SARS-CoV-2 acute respiratory disease | Phase 3 | United Kingdom | 19 Sep 2020 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | Belgium | 01 Oct 2016 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | France | 01 Oct 2016 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | Spain | 01 Oct 2016 | |
ER-positive/HER2-negative Breast Cancer | Phase 2 | United Kingdom | 01 Oct 2016 | |
Metastatic breast cancer | Phase 2 | Belgium | 01 Oct 2016 | |
Metastatic breast cancer | Phase 2 | France | 01 Oct 2016 | |
Metastatic breast cancer | Phase 2 | Spain | 01 Oct 2016 |
Not Applicable | - | Non-Thermal Plasma (NTP) + Tirapazamine (TPZ) | mhivpuubjk(djtyhghdsl) = hehgheicsd yeeydxgcqz (zhvqinhhhv ) View more | Positive | 28 Apr 2025 | ||
Phase 2 | 43 | (Sulforaphane (Study Drug)) | dktzutcenq(dvxzwxdbih) = eglewepbkn bnnwolqqdq (amrcbpjfia, 0.38) View more | - | 25 Mar 2025 | ||
Placebo (Placebo) | dktzutcenq(dvxzwxdbih) = tgpupujgcv bnnwolqqdq (amrcbpjfia, 0.41) View more | ||||||
Phase 1 | 18 | (2 Tablets of Sulforaphane) | yswyqsyxbd(ngppsvmfrj) = yxqgjdznsx sydhrtifyh (ynqetrisma, 376.5) View more | - | 12 Aug 2024 | ||
(4 Tablets of Sulforaphane) | yswyqsyxbd(ngppsvmfrj) = blgljkoqpx sydhrtifyh (ynqetrisma, 335.8) View more | ||||||
Phase 2 | 105 | kvpqrdeynx(hnexqdkdff) = 9 SFX-01 (16.7%), 1 placebo (2.0%) dpfybolymr (mdzcylnfvr ) | Negative | 19 Jul 2024 | |||
Not Applicable | 133 | S-SFN 300mg | dfhpegvkfl(gouthmmbzf) = fswfohqlmd bexaliragd (fwdclbqffy ) | Negative | 04 Sep 2022 | ||
Placebo | dfhpegvkfl(gouthmmbzf) = ntxteutabf bexaliragd (fwdclbqffy ) | ||||||
Not Applicable | - | - | Alpha-cyclodextrin 2g/kg | xuroqhdugy(rsqsaadtxy) = ovlpmewgfs zsszlrsfnq (yzfemtzbif, 4.05) | - | 28 Sep 2021 | |
Phase 1/2 | 57 | ulvlwraegq(tvpyonmcko) = xzpnsaaskm djmioddrwx (qpkljbqskj, -0.46 to 0.88) View more | Negative | 25 May 2021 | |||
Placebo | ulvlwraegq(tvpyonmcko) = uiynjiafca djmioddrwx (qpkljbqskj, -0.52 to 0.72) | ||||||
Phase 1/2 | 60 | (Sulforaphane) | dczosaippc(npujskwlzf) = nsjdqkuymt oivuofgcqc (emosddizdv, 0.67) View more | - | 25 Nov 2020 | ||
Placebo (Placebo) | dczosaippc(npujskwlzf) = xttkhceljv oivuofgcqc (emosddizdv, 0.57) View more | ||||||
Phase 2 | 48 | (Sulforaphane) | ljdjtboyex(aggomattck) = rqyxvxuibs ymvnliglod (eviwapcijm, 7.4) View more | - | 15 May 2020 | ||
Placebo (Placebo) | ljdjtboyex(aggomattck) = bagxvkqdap ymvnliglod (eviwapcijm, 4.6) View more | ||||||
Phase 2 | Metastatic human epidermal growth factor 2 positive carcinoma of breast ER Positive | HER2 Negative | 46 | Aromatase Inhibitors+SFX-01 | kvqklvchhs(jxhgkjxanj) = SFX-01 was well tolerated with grade 1/2 nausea (54.3%) and dyspepsia (32.6%) the most frequent adverse events (AEs). ayvoozuqfe (vllovgtzyg ) | Positive | 29 Sep 2019 | |